Yanina Eberhard
Overview
Explore the profile of Yanina Eberhard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Simpson C, Hurren R, Kasimer D, MacLean N, Eberhard Y, Ketela T, et al.
Apoptosis
. 2012 Apr;
17(7):666-78.
PMID: 22488300
Acquisition of resistance to anchorage dependant cell death, a process termed anoikis, is a requirement for cancer cell metastasis. However, the molecular determinants of anoikis resistance and sensitivity are poorly...
2.
Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, et al.
Cancer Cell
. 2011 Nov;
20(5):674-88.
PMID: 22094260
To identify FDA-approved agents targeting leukemic cells, we performed a chemical screen on two human leukemic cell lines and identified the antimicrobial tigecycline. A genome-wide screen in yeast identified mitochondrial...
3.
Eberhard Y, Gronda M, Hurren R, Datti A, MacLean N, Ketela T, et al.
Oncotarget
. 2011 Mar;
2(3):186-96.
PMID: 21406729
Evasion of death receptor ligand-induced apoptosis contributs to cancer development and progression. To better understand mechanisms conferring resistance to death ligands, we screened an siRNA library to identify sequences that...
4.
Wood T, Dalili S, Simpson C, Sukhai M, Hurren R, Anyiwe K, et al.
Mol Cancer Ther
. 2010 Jan;
9(1):246-56.
PMID: 20053768
Evasion of death receptor ligand-induced apoptosis represents an important contributor to cancer development and progression. Therefore, molecules that restore sensitivity to death receptor stimuli would be important tools to better...
5.
Eberhard Y, McDermott S, Wang X, Gronda M, Venugopal A, Wood T, et al.
Blood
. 2009 Jul;
114(14):3064-73.
PMID: 19589922
Off-patent drugs with previously unrecognized anticancer activity could be rapidly repurposed for this new indication. To identify such compounds, we conducted 2 independent cell-based chemical screens and identified the antimicrobial...
6.
Wood T, Dalili S, Simpson C, Hurren R, Mao X, Saiz F, et al.
Mol Cancer Ther
. 2008 Nov;
7(11):3546-55.
PMID: 19001437
Evasion of death receptor ligand-induced apoptosis is an important contributor to cancer development and progression. Therefore, molecules that restore sensitivity to death receptor stimuli would be important tools to better...
7.
Mao X, Stewart A, Hurren R, Datti A, Zhu X, Zhu Y, et al.
Blood
. 2007 Sep;
110(12):4047-54.
PMID: 17875808
The oncogene c-maf is frequently overexpressed in multiple myeloma cell lines and patient samples and contributes to increased cellular proliferation in part by inducing cyclin D2 expression. To identify regulators...
8.
Eberhard Y, Burgos E, Gagliardi J, Vullo C, Borosky A, Pesoa S, et al.
Arch Dermatol Res
. 2005 Jan;
296(7):309-13.
PMID: 15650893
The aim of this study was to assess whether tumor necrosis factor alpha (TNF-alpha), transforming growth factor beta1 (TGF-beta1) and interleukin-10 (IL-10) polymorphisms are among the factors influencing the development...
9.
Eberhard Y, Ortiz S, Ruiz Lascano A, Kuznitzky R, Serra H
BMC Immunol
. 2004 Apr;
5:7.
PMID: 15109401
Background: Expression of murine CCL21 by dermal lymphatic endothelial cells (LEC) has been demonstrated to be one of the most important steps in Langerhans cell emigration from skin. Previously, our...
10.
Serra H, Eberhard Y, Martin A, Gallino N, Gagliardi J, Baena-Cagnani C, et al.
Int Arch Allergy Immunol
. 2004 Jan;
133(1):64-71.
PMID: 14726633
Chemokines are important players in the development of allergic contact dermatitis (ACD). The participation of secondary lymphoid tissue chemokine (CCL21) is essential in the induction of the disease due to...